CY1111060T1 - Νουκλεϊκα οξεα χρησιμα για την πυροδοτηση της θνησιμοτητας κυτταρων ογκου - Google Patents

Νουκλεϊκα οξεα χρησιμα για την πυροδοτηση της θνησιμοτητας κυτταρων ογκου

Info

Publication number
CY1111060T1
CY1111060T1 CY20101101190T CY101101190T CY1111060T1 CY 1111060 T1 CY1111060 T1 CY 1111060T1 CY 20101101190 T CY20101101190 T CY 20101101190T CY 101101190 T CY101101190 T CY 101101190T CY 1111060 T1 CY1111060 T1 CY 1111060T1
Authority
CY
Cyprus
Prior art keywords
acids useful
volume cell
cell mortality
nuclear acids
fire volume
Prior art date
Application number
CY20101101190T
Other languages
Greek (el)
English (en)
Inventor
Marie Dutreix
Jian-Sheng Sun
Original Assignee
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie filed Critical Institut Curie
Publication of CY1111060T1 publication Critical patent/CY1111060T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/13Decoys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CY20101101190T 2003-10-24 2010-12-23 Νουκλεϊκα οξεα χρησιμα για την πυροδοτηση της θνησιμοτητας κυτταρων ογκου CY1111060T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292666A EP1526177A1 (en) 2003-10-24 2003-10-24 Nucleic acids useful for triggering tumor cell lethality
EP04817274A EP1675954B1 (en) 2003-10-24 2004-10-25 Nucleic acids useful for triggering tumor cell lethality

Publications (1)

Publication Number Publication Date
CY1111060T1 true CY1111060T1 (el) 2015-06-11

Family

ID=34384721

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101190T CY1111060T1 (el) 2003-10-24 2010-12-23 Νουκλεϊκα οξεα χρησιμα για την πυροδοτηση της θνησιμοτητας κυτταρων ογκου

Country Status (15)

Country Link
US (1) US7595302B2 (https=)
EP (2) EP1526177A1 (https=)
JP (2) JP4743789B2 (https=)
CN (1) CN1871350B (https=)
AT (1) ATE485375T1 (https=)
AU (1) AU2004284228B2 (https=)
CA (1) CA2542942C (https=)
CY (1) CY1111060T1 (https=)
DE (1) DE602004029699D1 (https=)
DK (1) DK1675954T3 (https=)
ES (1) ES2354359T3 (https=)
PL (1) PL1675954T3 (https=)
PT (1) PT1675954E (https=)
SI (1) SI1675954T1 (https=)
WO (1) WO2005040378A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476729B2 (en) * 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EP1944369A1 (en) * 2007-01-12 2008-07-16 The Centre National de la Recherche Scientifique Dbait and its standalone uses thereof
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
US9205099B2 (en) 2010-06-22 2015-12-08 Dna Therapeutics Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
AU2015202211B2 (en) * 2010-06-22 2016-09-01 Centre National De La Recherche Scientifique Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
EP2527440A1 (en) * 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
AU2014316676B2 (en) * 2013-09-04 2020-07-23 Csir Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression
EP3919621A1 (en) * 2014-06-23 2021-12-08 The General Hospital Corporation Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリInstitut Curie 癌を処置するためのDbait分子とPARPインヒビターとの組合せの使用
US10821128B2 (en) * 2016-03-01 2020-11-03 Onxeo Treatment of cancer by systemic administration of Dbait molecules
WO2017186882A1 (en) 2016-04-29 2017-11-02 Onxeo A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules
US10876116B2 (en) 2016-07-15 2020-12-29 The Board Of Regents Of The University Of Oklahoma Anti-ARID3a treatments for inflammatory disorders
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
CN108261548B (zh) * 2018-01-10 2020-04-10 浙江大学 一种纳米复合物及其制备方法和应用
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
CA3097044A1 (en) 2018-04-17 2019-10-24 The General Hospital Corporation Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
WO2020127965A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
JP2025500922A (ja) 2021-12-16 2025-01-15 ヴァレリオ・セラピューティクス 新規のコンジュゲートされた核酸分子及びその使用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ255028A (en) * 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
US6441158B1 (en) * 1997-12-31 2002-08-27 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
EP0978561A1 (en) * 1998-08-07 2000-02-09 Hoechst Marion Roussel Deutschland GmbH Antisense oligonucleotides for the inhibition of VEGF expression
AU2002241952A1 (en) * 2001-01-22 2002-07-30 Genta Incorporated Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
CA2476468A1 (en) 2002-02-13 2003-08-21 Medbridge, Inc. Protein carrier system for therapeutic oligonucleotides
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes

Also Published As

Publication number Publication date
WO2005040378A1 (en) 2005-05-06
CN1871350B (zh) 2014-10-15
DK1675954T3 (da) 2011-01-10
EP1675954A1 (en) 2006-07-05
AU2004284228B2 (en) 2010-04-08
PL1675954T3 (pl) 2011-04-29
JP4743789B2 (ja) 2011-08-10
SI1675954T1 (sl) 2011-01-31
ATE485375T1 (de) 2010-11-15
ES2354359T3 (es) 2011-03-14
CA2542942C (en) 2014-04-29
JP2007510405A (ja) 2007-04-26
US20070197458A1 (en) 2007-08-23
JP2011126897A (ja) 2011-06-30
PT1675954E (pt) 2010-12-27
EP1526177A1 (en) 2005-04-27
US7595302B2 (en) 2009-09-29
JP5662822B2 (ja) 2015-02-04
DE602004029699D1 (de) 2010-12-02
CN1871350A (zh) 2006-11-29
CA2542942A1 (en) 2005-05-06
AU2004284228A1 (en) 2005-05-06
EP1675954B1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
CY1111060T1 (el) Νουκλεϊκα οξεα χρησιμα για την πυροδοτηση της θνησιμοτητας κυτταρων ογκου
HRP20070012A2 (hr) Imunostimulatorski oligonukleotidni multimeri
CY1124931T1 (el) Αντιμετωπιση της φαινυλκετονουριας με bh4
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
TR200202196T2 (tr) Homolog yeniden kombine etmeyi iyileştirme yöntemleri
MY131964A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR049723A1 (es) Sustancias activas para el aumento de la defensa frente a patogenos en plantas y metodos para su deteccion
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
WO2004037977A3 (en) Use of chimeric nucleases to stimulate gene targeting
EP2003196A3 (en) Compositions and methods for treating and diagnosing cancer
DE60310202D1 (de) Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
AR086031A2 (es) Un metodo para remover al menos una secuencia transgenica en una celula vegetal o planta
EP1458870A4 (en) COMPOSITIONS AND METHODS USING ARNS, AMPHIPATHIC COMPOUNDS AND POLYCATIONS
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
SG158133A1 (en) Method for reversing multiple resistance in animal cells
AR054526A1 (es) Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)
AR039185A1 (es) Celulas hospedantes que tienen propiedades mejoradas de supervivencia celular y metodos para generar estas celulas
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
MY142040A (en) Nitrosophenols and c-nitrosoanilines as polymerization inhibitors
BR9913132A (pt) Nucleotìdeos da antitrombina e proteìnas do moscão
WO2005007098A3 (en) Nucleic acid therapy to enhance cartilage repair
RU2003101855A (ru) Средство, нормализующее структуру и функции органов и тканей, стимулирующее репарирование повреждений, обладающее противовирусной активностью, и способ его получения
WO2003090778A3 (en) Dna vaccine combined with an inducer of tumor cell apoptosis
DK1507863T3 (da) Plasmidstabilisering in vivo
AU1248602A (en) Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids